Epimutations, Inheritance and Causes of Aberrant DNA Methylation in Cancer by Mossman, David & Scott, Rodney J
H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(2) 75
Hereditary Cancer in Clinical Practice 2006; 4(2) pp. 75-80
Epimutations, Inheritance and Causes of Aberrant DNA Methylation in Cancer
David Mossman
1, Rodney J. Scott
1,2
1Discipline of Medical Genetics, Faculty of Health, University of Newcastle, Hunter Medical Research Institute, NSW, Australia; 2Division of Genetics, Hunter Area
Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia
Key words: aberrant methylation, epimutation, epigenetic inheritance, regulation of methylation
Corresponding author: David Mossman, e-mail: David.mossman@studentmail.newcastle.edu.au
Submitted: 3 May 2006
Accepted: 20 May 2006
A Ab bs st tr ra ac ct t
Epigenetic aberrations such as global hypomethylation and gene-specific hypermethylation are key events that
underlie tumour development. Such scenarios are brought about by the loss of control of methylation patterns
which typically are reversed in neoplasia in comparison to normal states. Despite the methylation process being
termed epigenetic, suggesting that it is not a heritable condition, there is strong evidence in mouse models
suggesting that epimutations within the germline may provide a mechanism through which methylation variations
can be transmissible to offspring. The first half of the review will focus on the nature of methylation-induced
gene silencing and transmission of this information through the germline. The latter half will focus on the cause
of aberrant DNA methylation.
I In nt tr ro od du uc ct ti io on n
In normal cells, repetitive elements such as long
interspersed nucleotide elements (LINE), Alu repeats and
satellite sequences, which make up almost half of the
entire genome, are methylated. As this contributes largely
to the level of global methylation, it is no surprise that
these regions are the most drastically affected by
hypomethylation, and the stability that the methylation
once conferred to the chromosomes is lost. Supporting
this is strong evidence to show that global
hypomethylation plays a crucial role in causing genomic
instability in colorectal carcinogenesis [1]. Such
hypomethylation is observed in cancer cells and can be
used as an indicator of genomic methylation levels [2].
Alternatively, gene specific hypermethylation is another
mechanism which can initiate carcinogenesis. This
mechanism of gene silencing is demonstrated by the
correlation of methylated promoters with a subsequent
decrease of corresponding gene expression. Some
examples of genes methylated in cancer are summarised
in Table 1. Co-existence of global hypomethylation and
gene-specific hypermethylation is common in cancer
and will be discussed in more detail later in this review.
Knudson’s two-hit hypothesis [3] requires that both
alleles of a tumour-suppressing gene be altered for
disease progression to occur. Germline mutations
commonly represent the first hit of one allele, whilst the
second hit typically arises from a sporadic mutation or
loss of heterozygosity that affects the second allele
(Figure 1a). With the increasing detection of methylated
promoters, refinements to Knudson’s hypothesis can
be made to accommodate epigenetic silencing. The
MLH1 gene is widely studied and will be used in the
following examples. One such scenario of epigenetic
silencing includes methylation acting as the second hit,
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allele (Figure 1b) and has been detected on genes such
as RB1 [4], VHL [5], MLH1 [6] and BRCA1 [7]. A typical
example of this is evident in the colorectal cancer cell
line HCT116, which has a truncating mutation in one
allele of the p16 gene. The wild-type allele however is
subjected to methylation whilst the mutated allele
remains unmethylated, showing how co-operatively
these two mechanisms can silence genes [8]. Thirdly is
a mechanism in which both alleles of a gene become
deactivated by methylation. Sporadic cases of colon
cancer are frequently the result of methylated MLH1
[9]. Methylation may even act as the first and second
hits as illustrated in Figure 1c. As will be discussed
shortly, certain individuals possess a silenced MLH1
allele in all cells of the body, and a second event will
disrupt the wild-type allele in carcinomas [10].
I In nh he er ri it ta an nc ce e  o of f  e ep pi im mu ut ta at ti io on ns s
Epimutations have been shown to be transmitted
clonally, and the thought that an epimutation can be
transferred through the germline has received
increasing attention in past years. 
Roemer et al. [19] demonstrated that they could
induce altered gene expression in mice by nuclear
transfer with another cell of different genotype. In doing
so, this induced methylation of two genes: major
urinary protein (Mup) and olfactory marker protein
(Omp). These changes were found to still be in place
when the mice reached adulthood, and intriguingly the
offspring were found to have increased methylation of
the two genes when compared with normal controls.
This was the first documented example of epigenetic
inheritance, and raised questions as to whether
a similar event would be possible in humans.
Ideal candidates were identified by screening
populations of people who had the characteristics of
a disease, yet lacked any mutation in the genes
associated with the disease. Three groups which have
done this recognised individuals who were mutation
negative for genes associated with hereditary
non-polyposis colorectal cancer (HNPCC), yet displayed
phenotypic similarities to a person with the condition
[10, 20-22]. These studies have identified several
individuals that show mono-allelic methylation of the
MLH1 allele in peripheral blood [20] and additionally
in buccal mucosa and hair follicles [10, 21, 22]. As these
changes were present soma-wide, they are all indicative
of a parental germline change in MLH1 (inherited
epimutation) or an event soon after fertilization.
Subsequently, the next task was to ascertain whether the
methylated allele could be transmitted to offspring and
establish a mono-allelic methylation pattern. The
transmission of affected alleles from parents to offspring
can be monitored by detecting the presence of
a polymorphism within the MLH1 promoter. In one family
it was found that the methylated paternal allele (present
in patient TT) had been passed to a daughter, but it did
not attract the methylation as it had in the parent [10].
In a second unrelated family, a male (patient ST) carried
a methylated maternal allele, but the allele was not
silenced in the mother, or siblings who inherited the
T Ta ab bl le e 1 1. .   Genes frequently found methylated in bowel, endometrial,
urothelial and breast tumours
T Tu um mo ou ur r   l lo oc ca at ti io on n G Ge en ne es s   m me et th hy yl la at te ed d R Re ef fe er re en nc ce e
bowel MLH1 11, 12
p14 11, 12
p16 11, 12
APC 11, 12
MGMT 12
RASSF1A 12
CDH1 12
endometrial p16 13
MLH1
urothelial p14 14
p16
E-Cadherin (CDH1)
GSTP1
breast BRCA1 15
COX2 16
E-Cadherin (CDH1) 17
HIC1 18
F Fi ig g. . 1 1. .   Alternate mechanisms of Knudson’s two-hit hypothesis. Diagram
a) illustrates the original hypothesis in which two ‘hits” affect both
alleles of a particular gene. Diagram b) demonstrates methylation
occurring as the second hit in unison with a pre-existing mutation.
Diagram c) represents an individual with a soma-wide epimutation.
The second allele can then also be lost due to methylation
a a) )   
b b) )
c c) )
f fi ir rs st t   h hi it t s se ec co on nd d   h hi it t
=mutation
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corresponding allele [22]. Details of a third family are
less detailed; two children of an affected mother (patient
VT) possessed normal MLH1 alleles but the status of
a third child and the father were not known [10]. Despite
neither patient VT nor TT carrying a mutation within
a known HNPCC associated gene, they were part of
families with histories of the disease. This may suggest
that more complex genetic interactions or a gene not
linked to MLH1 was causative of their condition rather
than a distinct mutation.
The most compelling evidence for transmission of
epimutated alleles is shown by the analysis of patient
TT’s spermatozoa. Following PCR, cloning and
hybridization with a methylation-specific probe, 5
of 526 colonies showed a methylated MLH1 promoter.
Affected spermatozoa could potentially be transmitted
to offspring, rendering them more susceptible to
developing disease. Despite only 1% of spermatozoa
being affected, this revealed that a) the majority of
methylation present is removed during meiosis, and b)
that transmission to offspring would be rare, but
possible. Cases reported so far have yet to identify the
transmission of a methylated allele, so the evidence
would support an early epimutational event rather than
an inherited predisposition as the cause, although the
number of cases studied is small and parental genetic
information cannot always be obtained. If indeed the
methylated allele was transmitted in that state, the
methylation may even be removed early in
embryogenesis in the wave of demethylation [23].
Future work may prove epigenetic inheritance using
other genes that are commonly affected in disease.
A Ab be er rr ra an nt t  m me et th hy yl la at ti io on n  p pa at tt te er rn ns s
A common characteristic of cancer cells is a reversal
of normal methylation patterns; a high level of
methylation is observed in specific promoter regions
and a global decrease in genomic methylation [24]. It
would appear that these features are a cause rather
than a consequence of the cancer as alterations can
be identified in the early stages of cancer development.
For this reason, the mechanism which regulates the
methylation process has been highly sought after, yet
remains elusive. Several facets which may affect the
normal functioning of methylation controlled gene
regulation will be discussed here.
D DN NM MT T  o ov ve er r- -e ex xp pr re es ss si io on n
Among the most common explanations for the
disturbance of regular methylation patterns is the
up-regulation of the methyltransferase enzymes. On
numerous occasions it has been demonstrated that
DNMT levels are elevated in several diverse forms of
cancer such as leukaemia [25], endometrial cancer
[26] and lung cancer [27]. It could be argued that the
down-regulation of maintenance methylation by
DNMT1 may lead to hypomethylation, whilst
simultaneous up-regulation of the de-novo
methyltransferases DNMT3a and 3b could account for
the increase in aberrantly methylated promoters.
Kimura et al. [28] showed that DNMT1 maintenance
methyltransferase expression was not correlated with
the extent of DNA hypomethylation in transitional cell
carcinomas; however, there was a decrease of DNMT1
expression relative to cell proliferation. Addressing the
hypermethylation of certain promoters, it was shown
that DNMT3b levels were higher than corresponding
normal tissue, although DNMT3a levels were not.
While it seems a likely explanation in this scenario, it
is not always so straightforward. Observations include
simultaneous up- and down-regulation of de novo
(DNMT3a and 3b) and maintenance (DNMT1)
transferases, and the level of expression of the
methyltransferases is sometimes variable within the
same cell type [29]. 
Doubt also surrounds whether over-expression of
methyltransferases is responsible for hypermethylation.
Eads et al. [30] showed that the expression levels of
DNMT1, 3a and 3b did not correlate with the frequency
or extent of hypermethylation of APC, ESR1, p16 or
MLH1 in colorectal adenocarcinomas. Whilst the
methyltransferases were up-regulated when normalised
with β-actin and an RNA polymerase large subunit, they
were not significantly up-regulated when normalised
with proliferation-dependant H4F2 or PCNA. This
suggests that although the methyltransferase levels
appear to be increased in many cell types, they may in
fact not be when they are normalised with other
proliferation-dependant genes.
Amid the evidence of altered levels and variations
of expression levels, it would not seem logical that
simple up-regulation or down-regulation of one form
of methyltransferase would cause site-specific
hypermethylation in parallel with a global decrease in
methylation, but rather a co-ordinated alteration
between de novo and maintenance forms to explain
the aberrant methylation state.
S Su ub bt tl le e  C Cp pG G  i is sl la an nd d  d di if ff fe er re en nc ce es s
It is evident that some CpG islands are more often
affected than others by methylation, supported by the
observation that a cluster of genes is frequently
hypermethylated in several types of cancer cells [24].
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in the maintenance of genomic integrity, tumour
suppression and metastasis, and that these promoters
are unaffected in normal tissue. An example of such
is the well characterised MLH1 gene in bowel cancer
syndromes. This gene is one of four genes which confer
a higher susceptibility to HNPCC, yet MLH1 is the only
one of the four which becomes methylated. 
It would seem reasonable to suggest that some
CpG islands may be more likely to succumb to
methylation based on CpG island size, GC content,
CpG frequency, chromosomal location or promoter
association. An experiment by Feltus et al. [31] in 2003
examined the methylation state of several CpG islands
in cells over-expressing DNMT1. The majority of the
CpG islands tested were resistant to methylation, but
a small proportion (3.8%) were found to be
hypermethylated by DNMT1. Using this information
they identified seven sequence patterns that were
capable of discriminating between methylation prone
and resistant islands with a success rate of 87%. These
sequences would appear to confer some kind of
susceptibility or resistance to methylation, possibly
similar to the situation in which a non-methylated
imprinted allele is resistant to methylation. 
In this study, the number of methylated CpG islands
may have been biased, due to the over-expression of
the maintenance methyltransferase rather than the de
novo forms. Therefore the hypermethylated regions in
the study are in essence DNMT1 susceptible regions,
and it is possible that the number of methylated islands
would be higher if de novo methyltransferases were
over-expressed. Nonetheless, this study has shown that
no particular characteristic such as CpG frequency or
island size affects methylation susceptibility, but more
so a subset of DNA sequences which may attract or
repel methylation. In terms of initiating hypermethylation,
these sequences alone will not define the methylation
status of a particular gene, as non-methylated regions
in normal tissue will also have the same sequence.
D DN NA A  d de em me et th hy yl la at ti io on n
The issue of DNA demethylation is a major unknown
in the field of epigenetics. There has been some debate
that still continues over the presence and existence of
DNA demethylating enzymes. A demethylating enzyme
has been uncovered, but this acts on histones rather
than DNA [32]. The most controversy surrounds the
MBD2 gene, with one group claiming it has DNA
demethylating properties [33-35] whilst others continue
to find that it acts as a transcriptional repressor [36-
38]. Much work has been performed involving the gene
and there are numerous reports that support each side
of the debate that will not be discussed here. For details
of these, see references [33-38], in particular
reference 33, in which supporters of MBD2’s
demethylase action address issues raised by others
suggesting MBD2 is a transcriptional repressor.
At present, the identification of a bona fide
demethylase is yet to occur; however, should
a candidate be recognised, it will no doubt trigger
enormous interest in the particular gene’s role in cancer.
D Di ie et ta ar ry y  f fa ac ct to or rs s,,  i in nc cl lu ud di in ng g  f fo ol la at te e  m me et ta ab bo ol li is sm m
There are vast amounts of evidence that nutrition
obtained from dietary components has a major influence
on individual health status, and there are at least two
pathways with which nutrient intake can affect
methylation, as reviewed in [39], and more recently [40].
The first of these simply states that the supply of nutrients
affects the supply of methyl groups required for
methylation. Numerous dietary components are known
to influence DNA methylation status, and folate, choline
and vitamin B12 feature highly in the literature. Various
forms of folate are converted into intermediates that are
ultimately converted to S-adenosyl-methionine, the
chemical substrate with which the methyltransferase
enzymes obtain methyl groups for attachment to the
DNA [41]. The precise role of folate and the effects of
its absence are complex (for a review see reference 42),
and its importance is due to its function as a precursor
methyl-donor. Vitamin B12 is a co-factor for many
enzymatic processes leading to the methylation of DNA.
Rats fed a diet deficient in B12, but not severe enough
to cause illness, were observed to have hypomethylated
genomic DNA in colon tissue in comparison to
appropriate controls, illustrating that a vitamin deficient
diet can restrict DNA methylation.
The second mechanism in which diet can influence
methylation relies on the effects of trace dietary
components interfering with methyltransferase processes.
A selenium deficiency has been shown to cause DNA
hypomethylation in rat colon DNA, while prolonged
cadmium exposure also initiates hypomethylation
followed by hypermethylation, suggesting that a feedback
mechanism is involved [43]. In the same study, it was
suggested that cadmium inhibited the methyltransferases
via an interaction with the DNA binding domain rather
than the catalytic domain. Nickel [44] and alcohol [45]
have also been observed to affect DNMT activity,
although the precise mechanism of this is not understood. 
M Me et th hy yl la at ti io on n  s sp pr re ea ad di in ng g  
The expansion of existing methylation to cover
neighbouring non-methylated sites is another
hypothesis to explain aberrantly silenced genes. 
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An experiment by Tollefsbol & Hutchinson [46] has
shown that using synthetic oligonucleotides, pre-existing
methylation was able to spread to neighbouring CpG
islands. It was found that this pseudo-DNA with partial
CpG methylation was more likely to undergo de novo
methylation on non-affected CpGs than a control without
pre-existing methylation. This would suggest that the
methylation was required for the methyltransferases to
recognise the DNA and spread the methylation.
Furthermore, mammalian methyltransferases were the only
proteins necessary to induce this state, eliminating the
notion that other factors are required for the expansion.
These results provide evidence which supports the
spreading of methylation from ordinarily methylated
DNA regions to areas which would not usually be
methylated. The precise role that this method plays in
disease initiation is not known, and methylation
spreading has a weaker justification for the aberrant
methylation observed in cancer, particularly global
hypomethylation. However, if the spreading of
methylation to normally unaffected regions occurs in
conjunction with another mechanism such as
down-regulation of maintenance methylation, it could
provide a clearer pathway in which aberrant
disease-causing methylation patterns arise.
C Co on nc cl lu us si io on n
Epimutation of several genes has been shown to
cause disease, and is equivalent to mutations within
the same gene, but is a reversible trait. Inheritance of
epimutations is an interesting facet of genetics, which
may possibly play a role in a small percentage of
cancer cases. There is evidence of its occurrence in
mammals, yet definite proof of its existence in humans
is yet to be demonstrated.
With regards to the regulation of methylation, the
five mechanisms discussed each provide a possible
explanation for aberrant DNA methylation. However,
there does not seem to be one theory that can
conclusively account for the abnormal methylation
patterns in cancer, namely localised hypermethylation
and genome-wide hypomethylation. A combination of
events such as any of those discussed above with other
environmental and other unknown genetic factors may
have a cumulative effect on abnormal DNA methylation.
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